Bixiye
QP41-21 Commercial and MHCP Pharmacy Benefit Exclusion for Qutenza®
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Natiijooyinka Raadinta
Soo bandhiga 2201 - 2210 ee natiijooyinka 3690
Bixiye
QP40-21 Commercial Pharmacy Benefit Update – New and Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective July 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Bixiye
QP42-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Agents
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Bixiye
P29-21 Reimbursement Change for Licensed Professional Clinical Counselors (LPCC)
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
P21-21 RAP Claims Required for Home Care Claims Effective July 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
P26-21 Sequestration Suspension for Medicare Lines of Business Extended
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
P20-21 Removal of Four Medicare Platinum Blue Prior Authorization Requirements — Effective June 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
P28-21 Updated Prior Authorization Requirements for Psychological and Neuropsychological Testing for Commercial and Medicare Advantage Products
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
2021 May Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
QP2-21 Update for New to Market Medical Drugs: Aducanumab, Casimersen, Evinacumab, Idecabtagene Vicleucel, and Pegunigalsidase Alfa
Taariikhda uu dhaqangalayo Barnaamijka: Jan 13, 2021